This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.We will solicit projects on a yearly basis. The projects will be separately evaluated by the steering committee and voting will be done by secret ballot. We may award two $45,000 grants, four $22,500 grants, or any combination, depending on the quality and scientific vision of the individual proposal. A selective advantage will be given to projects that incorporate and unify two or more areas of research and/or bridge specific Programs within OMRF, and this will be announced at the time the projects are solicited. Specific attention will be given to projects that expand/enhance our goals of integrating Programs in Immunology at OMRF. Priority will go to new investigators. It would require a very unusual set of extenuating circumstances for the COBRE steering committee to award such grants to anyone above the assistant member level. Projects would be further reviewed by our External Scientific Committee, followed by a request for approval from NCRR. This rigorous selection process will function to insure stringently that only research projects of the very highest scientific caliber are funded by this money.The steering committee will appoint mentors for the pilot projects according to the stratified mentoring process described in this COBRE application. It is critically important that the review committee be made aware that these projects will be awarded only to independent scientists, and will not be used to enhance the laboratories of any of our senior faculty. This would be a clear misuse of these funds, and represents the antithesis of the supportive research culture we are striving to create at OMRF.As we did in our first COBRE award, we objectively evaluate individual outcomes of the funded pilot projects, improving and extending the criteria for measurement during this process. Since the funded Pilot Project scientists will almost certainly be at the beginning of their careers, this process will be simplified. Each new grant application, every paper, meeting presentation and other measurable criteria such as citations of a given publication will be carefully monitored by the mentoring team, as we recognize that we have a great responsibility to make certain that we not only fund the most promising research, but also document for peer review the fact that these funds have been wisely expended. The PI of the COBRE has been reducing his personal research commitment each year and will take the evaluation of research progress resulting from this COBRE award as a personal mentoring responsibility. Each pilot project recipient will be required to report his/her progress six and twelve months after the receipt of funds. Except under very exceptional circumstances, we do not anticipate that anyone will receive these funds more than once. These funds are intended to provide the necessary support to young scientists that will allow them to produce the preliminary data necessary for strong and competitive NIH applications. Based upon the recommendations of the EAC we also funded a Human Antibody Core for $40,000 for the upcoming budget period.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
Exploratory Grants (P20)
Project #
5P20RR015577-09
Application #
7720057
Study Section
Special Emphasis Panel (ZRR1-RI-8 (01))
Project Start
2008-03-01
Project End
2009-02-28
Budget Start
2008-03-01
Budget End
2009-02-28
Support Year
9
Fiscal Year
2008
Total Cost
$203,452
Indirect Cost
Name
Oklahoma Medical Research Foundation
Department
Type
DUNS #
077333797
City
Oklahoma City
State
OK
Country
United States
Zip Code
73104
Hu, Zihua; Jiang, Kaiyu; Frank, Mark Barton et al. (2018) Modeling Transcriptional Rewiring in Neutrophils Through the Course of Treated Juvenile Idiopathic Arthritis. Sci Rep 8:7805
Hu, Zihua; Jiang, Kaiyu; Frank, Mark Barton et al. (2016) Complexity and Specificity of the Neutrophil Transcriptomes in Juvenile Idiopathic Arthritis. Sci Rep 6:27453
Molineros, Julio E; Maiti, Amit K; Sun, Celi et al. (2013) Admixture mapping in lupus identifies multiple functional variants within IFIH1 associated with apoptosis, inflammation, and autoantibody production. PLoS Genet 9:e1003222
Smith, Kenneth; Muther, Jennifer J; Duke, Angie L et al. (2013) Fully human monoclonal antibodies from antibody secreting cells after vaccination with Pneumovax®23 are serotype specific and facilitate opsonophagocytosis. Immunobiology 218:745-54
Dozmorov, Igor; Dominguez, Nicolas; Sestak, Andrea L et al. (2013) Evidence of dynamically dysregulated gene expression pathways in hyperresponsive B cells from African American lupus patients. PLoS One 8:e71397
Jiang, Kaiyu; Frank, Mark; Chen, Yanmin et al. (2013) Genomic characterization of remission in juvenile idiopathic arthritis. Arthritis Res Ther 15:R100
Kurien, Biji T; D'Sousa, Anil; Bruner, Benjamin F et al. (2013) Prolidase deficiency breaks tolerance to lupus-associated antigens. Int J Rheum Dis 16:674-80
Vaughn, Samuel E; Kottyan, Leah C; Munroe, Melissa E et al. (2012) Genetic susceptibility to lupus: the biological basis of genetic risk found in B cell signaling pathways. J Leukoc Biol 92:577-91
Gaddy, Jasmine R; Vista, Evan S; Robertson, Julie M et al. (2012) Rheumatic disease among Oklahoma tribal populations: a cross-sectional study. J Rheumatol 39:1934-41
Hughes, Travis; Adler, Adam; Merrill, Joan T et al. (2012) Analysis of autosomal genes reveals gene-sex interactions and higher total genetic risk in men with systemic lupus erythematosus. Ann Rheum Dis 71:694-9

Showing the most recent 10 out of 194 publications